MAR002 Study Initiated for Acromegaly Treatment Evaluation
A clinical trial has been initiated to evaluate the safety and tolerability of MAR002 administered subcutaneously in patients with acromegaly.
Asset / Drug
Drug and asset intelligence for MAR002 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.